Itraconazole in Treating Patients with Basal Cell Carcinoma

Inclusion Criteria

• Women who do not have child-bearing potential (history of hysterectomy, post-menopausal)
• Have a biopsy confirmed basal cell carcinoma (BCC) that measures at least 6 mm in size at the time of the initial evaluation (visit #1)
• Participant must be willing and comply with the requirements of the protocol
• Participant must have the ability to understand and communicate with the investigator
• Participant must provide informed consent

Exclusion Criteria

• Subject with significant congestive heart failure (CHF) or history of CHF, chronic renal failure, hepatic failure, neuropathy
• Subject with current skin diseases that the investigator feels is not safe for study participation including but not limited to severe atopic dermatitis, cutaneous T-cell lymphoma, erythroderma
• Subjects on systemic medications known to affect the Hedgehog pathway
• Subjects on cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, methadone, levacetylmethadol (levomethadyl), lovastatin, simvastatin, dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), cisapride, pimozide, methadone, levacetylmethadol (levomethadyl), quinidine
• Subjects with history of hypersensitivity to azoles
• Subjects with Gorlin syndrome
• Subjects on chronic immunosuppression, or who have a history of compromised immune function (e.g. history of or current malignancy other than BCC/squamous cell skin cancers)
• Subjects who do not speak English or have difficulty hearing or are otherwise impaired for providing informed consent and communicating with the investigator
• Subjects with a history of keloids or excessive scarring
• Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
• Women of child-bearing age/potential and/or able to conceive